Meet Senzime at AdvaMed 2014.
Senzime has been selected to present at AdvaMed 2014, the leading MedTech conference in North America.
Uppsala, September, 2014. Senzime has been selected to present at AdvaMed 2014, the leading MedTech conference in North America through the generous support of Johnson & Johnson scholarship. Lena Söderström CEO is attending.
Company Presentations connect innovative, early-stage medical device and diagnostic companies with venture capital and angel investors, corporate business development executives and other strategic partners. Company Presentations at AdvaMed 2014 will feature 60+ innovative, early-stage MedTech companies competitively selected to make 9-minute investor and business development presentations.
AdvaMed 2014 is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2014 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more.
When: October 6-8, 2014 Where: McCormick Place Chicago, IL
Senzime to present: 11.35 AM room 181 A, October 7
AdvaMed 2014: The MedTech Conference Announces Presenting Companies for Annual Conference
- More Than 60 Emerging MedTech Startups Selected for Company Presentations
Link to Company Presentations: http://advamed2014.com/go.cfm?do=Page.View&pid=92
For more information:
Lena Söderström CEO
TO THE EDITORS
Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. BioSenzTM is an analytical instrument that performs this task. Senzime's market leading partner, Applikon, has started the global launch of BioSenzTM. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures and dialysis care. For these purposes, the company develops the instrument CliniSenzTM. The company's share is listed on Aktietorget since 2008. www.senzime.com